| Today's Big NewsJul 10, 2023 |
| By Angus Liu After a major phase 2 win that stirred up much excitement within the oncology community, Merck has officially formulated a pivotal trial plan for its Moderna-partnered mRNA cancer vaccine mRNA-4157. |
|
|
|
| July 18-19, 2023 | Jersey City, NJ |  |
|
|
By Zoey Becker After a Delaware district court ruled a 2025 Entresto combination patent is invalid, Novartis will head to the U.S. Court of Appeals for the Federal Circuit in an effort to reverse the decision. The setback comes after the company won an Entresto patent fight against Mylan in a West Virginia court. |
By Andrea Park After experiencing a boom in 2021 to make up for the dearth of dealmaking in 2020, M&A moves and VC fundraising in the medtech industry have been on a steady downward slope. |
By Nick Paul Taylor Johnson & Johnson has seized on the cash crunch at Nanobiotix to pick up a phase 3 cancer prospect for $30 million upfront. The deal gives J&J global rights to a candidate, NBTXR3, that is designed to enhance the efficacy of radiotherapy to improve outcomes in tumor types including head and neck cancer. |
|
Thursday, July 20, 2023 | 12pm ET / 9am PT In this webinar, you will learn how to capture all healthcare services accurately using multiple datasets, the methodology to capture non-traditional HCP visits, what to look for in an affiliations dataset to help identify non-traditional HCP visits, and more. Register now. 
|
|
By Angus Liu Canada has canceled some COVID-19 vaccine deliveries from Novavax and will pay $350 million to fully compensate the company for those unused doses. The survival of the Maryland-based company now depends on the successful delivery of an updated COVID shot this fall. |
By Andrea Park Just a few months after getting back on track after pausing shipments of its Tablo hemodialysis system to secure an updated FDA clearance for at-home use of the technology, Outset Medical is facing another potential regulatory setback. |
By Nick Paul Taylor Duality Biologics has caught the eye of another global biotech. Months after inking a deal with BioNTech, the antibody-drug conjugate (ADC) specialist has granted BeiGene an option on a preclinical asset in return for a financial package worth up to $1.3 billion. |
By Fraiser Kansteiner Samsung Biologics said in a Monday regulatory filing that it’s inked a $390.9 million deal to help crank out Novartis drugs. The latest production pact builds on an earlier tie-up worth $81 million. |
By Conor Hale The diagnostics company Quanterix hopes to gain new ground following the FDA’s recent full approval of Eisai and Biogen’s Leqembi treatment for Alzheimer’s disease, with the launch of an ultrasensitive blood test and a storefront for healthcare providers. |
By James Waldron Earlier this year, GSK executives explained to Fierce Biotech why they felt the company’s push into oligonucleotides was such a good fit. Now, the British Big Pharma has added further depth to this strategy courtesy of a research collaboration with Elsie Biotechnologies. |
By Fraiser Kansteiner WuXi Biologics has unveiled a proposed spinoff and separate listing of WuXi XDC Cayman—a joint venture between WuXi Bio and WuXi STA bred to tackle contract research, development and manufacturing of bioconjugates, including antibody-drug conjugates, antibodies and other biologic intermediates. |
By Conor Hale Previously requiring a prescription, the company’s FDA-cleared muscle stimulation device—the newly rechristened Motive Knee—will now be available exclusively on its website, with prices starting at $399. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we discuss new HIV therapies, plus Humira's new biosimilar, foreign pharmaceutical investments, and the rest of the week's headlines. |
|
|---|
|
|
|
Tuesday, July 25, 2023 1pm ET / 10am PT New methods in scalable compute cloud environments not only accelerate drug discovery in a cost-effective manner, but benefit from reduced deployment time, accelerated GPU speed, and reduced infrastructure costs. Register now to learn more. 
|
|
Research The right sourcing strategy can help save of millions of dollars—learn about developing a strategy for sourcing the cGMP chemicals critical to your processes. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
eBook This eBook identifies the trends driving major change in the Medical Affairs (MA) function. It also outlines the strategic and tactical implications for MA leaders and team members. Sponsored by: Blue Matter, strategic consultants in the life sciences |
eBook Take a look at the reporting tools sponsors need to access insights earlier in the clinical trial enrollment funnel, so you can take informed actions. Sponsored by: OneStudyTeam |
Whitepaper Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
Whitepaper Explore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
Whitepaper Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| July 18-19, 2023 | Jersey City, NJ |
|
|
| |
|
